Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. (Q43711552)
Jump to navigation
Jump to search
scientific article published on 10 December 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. |
scientific article published on 10 December 2012 |
Statements
1 reference
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. (English)
1 reference
1 reference
Anna Dmoszynska
1 reference
Paul G Richardson
1 reference
Antonio Palumbo
1 reference
Kenneth C Anderson
1 reference
Dixie-Lee Esseltine
1 reference
Helgi van de Velde
1 reference
Nuriet K Khuageva
1 reference
Ofer Shpilberg
1 reference
Olga S Samoilova
1 reference
Maria-Victoria Mateos
1 reference
Andrew Cakana
1 reference
Maria Teresa Petrucci
1 reference
William Deraedt
1 reference
Michel Delforge
1 reference
Jesús F San Miguel
1 reference
Rudolf Schlag
1 reference
Martin Kropff
1 reference
Bin Jiang
1 reference
Kevin Liu
1 reference
10 December 2012
1 reference
1 reference
31
1 reference
4
1 reference
448-455
1 reference
Identifiers
1 reference
1 reference